Goserelin plus endocrine treatments maintained long-term clinical benefit in a male patient with advanced breast cancer

BACKGROUND: Goserelin plus aromatase inhibitors (AI) have already been used in male advanced breast cancer, but the cases that fulvestrantin male breast cancer are rare. CASE PRESENTATION: Here we report a case of long-term (3 years) response to Goserelin plus continuing endocrine treatments given f...

Descripción completa

Detalles Bibliográficos
Autores principales: Jiang, Hang, Wang, Tao, Jiang, Zefei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4326472/
https://www.ncbi.nlm.nih.gov/pubmed/25539790
http://dx.doi.org/10.1186/1477-7819-12-393
_version_ 1782356937391734784
author Jiang, Hang
Wang, Tao
Jiang, Zefei
author_facet Jiang, Hang
Wang, Tao
Jiang, Zefei
author_sort Jiang, Hang
collection PubMed
description BACKGROUND: Goserelin plus aromatase inhibitors (AI) have already been used in male advanced breast cancer, but the cases that fulvestrantin male breast cancer are rare. CASE PRESENTATION: Here we report a case of long-term (3 years) response to Goserelin plus continuing endocrine treatments given for a male advanced breast cancer. The patient prolongs his life with high life quality, and has more time with his family. CONCLUSION: Goserelin plus endocrine treatments may benefit male breast cancer.
format Online
Article
Text
id pubmed-4326472
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-43264722015-02-14 Goserelin plus endocrine treatments maintained long-term clinical benefit in a male patient with advanced breast cancer Jiang, Hang Wang, Tao Jiang, Zefei World J Surg Oncol Case Report BACKGROUND: Goserelin plus aromatase inhibitors (AI) have already been used in male advanced breast cancer, but the cases that fulvestrantin male breast cancer are rare. CASE PRESENTATION: Here we report a case of long-term (3 years) response to Goserelin plus continuing endocrine treatments given for a male advanced breast cancer. The patient prolongs his life with high life quality, and has more time with his family. CONCLUSION: Goserelin plus endocrine treatments may benefit male breast cancer. BioMed Central 2014-12-23 /pmc/articles/PMC4326472/ /pubmed/25539790 http://dx.doi.org/10.1186/1477-7819-12-393 Text en © Jiang et al.; licensee BioMed Central. 2014 This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited.
spellingShingle Case Report
Jiang, Hang
Wang, Tao
Jiang, Zefei
Goserelin plus endocrine treatments maintained long-term clinical benefit in a male patient with advanced breast cancer
title Goserelin plus endocrine treatments maintained long-term clinical benefit in a male patient with advanced breast cancer
title_full Goserelin plus endocrine treatments maintained long-term clinical benefit in a male patient with advanced breast cancer
title_fullStr Goserelin plus endocrine treatments maintained long-term clinical benefit in a male patient with advanced breast cancer
title_full_unstemmed Goserelin plus endocrine treatments maintained long-term clinical benefit in a male patient with advanced breast cancer
title_short Goserelin plus endocrine treatments maintained long-term clinical benefit in a male patient with advanced breast cancer
title_sort goserelin plus endocrine treatments maintained long-term clinical benefit in a male patient with advanced breast cancer
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4326472/
https://www.ncbi.nlm.nih.gov/pubmed/25539790
http://dx.doi.org/10.1186/1477-7819-12-393
work_keys_str_mv AT jianghang goserelinplusendocrinetreatmentsmaintainedlongtermclinicalbenefitinamalepatientwithadvancedbreastcancer
AT wangtao goserelinplusendocrinetreatmentsmaintainedlongtermclinicalbenefitinamalepatientwithadvancedbreastcancer
AT jiangzefei goserelinplusendocrinetreatmentsmaintainedlongtermclinicalbenefitinamalepatientwithadvancedbreastcancer

Ejemplares similares